Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative…

Peter Marks, director of the US FDA's Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the…

Judith Love, country president Sweden and oncology general manager for the Nordics region for Novartis, underlines the need for a new reimbursement…

BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New…

France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with…

The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics' CAR-T cell therapy CT053 for multiple myeloma…

Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory…

HB Chen, president of TaiwanBio Therapeutics, introduces the innovative stem cell company and elaborates on their patented cell expansion technique…

Emanuele Ostuni, head of cell & gene therapy for Novartis Oncology in Europe, outlines how stakeholders across the biopharmaceutical value chain…

Bayer's latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell…

Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities,…

PhRMA's Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the…